Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388648 | 0.98 | KDM4E (0.56) | KDM4EALDH1A1HRH3KMT2AMBTD1 | |
| SCHEMBL3387912 | 0.93 | KDM4E (0.60) | KDM4EALDH1A1HRH3KMT2AMBTD1 | |
| SCHEMBL3388657 | 0.92 | MAPK14 (0.60) | KDM4EALDH1A1HRH3KMT2AMBTD1 | |
| SCHEMBL3390277 | 0.90 | MAPK14 (0.60) | KDM4EALDH1A1HRH3KMT2AMBTD1 | |
| SCHEMBL3385483 | 0.87 | L3MBTL3 (0.48) | KDM4EALDH1A1HRH3MBTD1L3MBTL3 | |
| SCHEMBL3386857 | 0.86 | HRH3 (0.52) | KDM4EALDH1A1HRH3KMT2AL3MBTL1 | |
| SCHEMBL3390570 | 0.86 | NPC1 (0.51) | KDM4EALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL3386122 | 0.85 | HRH3 (0.52) | KDM4EALDH1A1HRH3KMT2AL3MBTL1 | |
| SCHEMBL3386140 | 0.85 | L3MBTL3 (0.49) | KDM4EALDH1A1HRH3KMT2AMBTD1 | |
| SCHEMBL3383892 | 0.85 | MAPK14 (0.64) | KDM4EALDH1A1HRH3KMT2AMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | KDM4E 1027/4885ALDH1A1 317/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.